https://doi.org/10.4081/monaldi.2024.3033
Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients
Accepted: September 17, 2024
SUPPLEMENTARY MATERIAL: 10
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Predictors of outcomes are essential to identifying severe COVID-19 cases and optimizing treatment and care settings. The respiratory rate-oxygenation (ROX) index, originally introduced for predicting the failure of non-invasive support in acute hypoxemic respiratory failure (AHRF), has not been extensively studied over time during hospitalization. This multicenter prospective observational study analyzed COVID-19-related AHRF patients admitted to eight Italian hospitals during the second pandemic wave. The study assessed the ROX index using receiver operator characteristic curves and areas under the curve with 95% confidence intervals to predict treatment failure, defined as endotracheal intubation (ETI) or death. A total of 227 patients (69.2% males) were enrolled, with a median arterial partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FIO2) ratio at admission of 248 (interquartile range: 170-295). Nearly one-third (29.5%) required ETI or died during hospitalization. Those who experienced treatment failure were older (median age 70 vs. 61 years, p<0.001), more likely to be current or former smokers (8.5% vs. 6.4% and 42.4% vs. 25.5%, p=0.039), had a higher prevalence of cardiovascular diseases (74.6% vs. 46.3%, p<0.001), and had a lower PaO2/FIO2 ratio at presentation (median 229 vs. 254, p=0.014). Gender, body mass index, and other comorbidities showed no significant differences. In patients who failed treatment, the ROX index was higher at presentation and worsened sharply by days 3 and 4. Conversely, in patients who survived without requiring ETI, the ROX index remained stable and reduced after 5-6 days. The ROX index’s predictive ability improved notably by day 3 of hospitalization, with the best cut-off value identified at 8.53 (sensitivity 75%, specificity 68%). Kaplan-Meier curves indicated that a ROX index of 8.53 or lower on days 1, 2, or 3 was associated with a higher risk of treatment failure. Thus, a single ROX index assessment on day 3 is more informative than its variability over time, with values of 8.53 or lower predicting non-invasive respiratory support failure in hospitalized COVID-19 patients.
Ethics Approval
This study was approved by the respective ethics committees involved (Comitato etico di Bergamo - n.308-20, 05/02/2021; Comitato etico della Brianza - EC approval on 02/04/2021; Comitato etico di Ferrara - n.373/2021/Oss/AOUFe, 22/04/2021; Comitato etico Ospedale Sacco Milano - n.2021/ST/091, 19/04/2021; Comitato etico di Palermo - n.3/2021, 31/03/2021; Comitato etico Policlinico Milano - n.433/2021, 23/04/2021; Comitato etico San Paolo Milano - n.965, 21/04/2021; Comitato etico di Verona - n.3171CESC, 11/03/2021).How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Pier Luigi Temporelli, Cardiopulmonary rehabilitation in patiens with heart failure and chronic pulmonary disease , Monaldi Archives for Chest Disease: Vol. 84 No. 1-2 (2015): Cardiac series
- C. Gramiccioni, G.E. Carpagnano, A. Spanevello, V. Turchiarelli, M.G. Cagnazzo, M.P. Foschino Barbaro, Airways oxidative stress, lung function and cognitive impairment in aging , Monaldi Archives for Chest Disease: Vol. 73 No. 1 (2010): Pulmonary series
- U. Yilmaz, G. Polat, N. Sahin, Ö. Soy, U. Gülay, CT in differential diagnosis of benign and malignant pleural disease , Monaldi Archives for Chest Disease: Vol. 63 No. 1 (2005): Pulmonary series
- Abhijeet Singh, Rajendra Prasad, Rajiv Garg, Surya Kant, Giridhar B. Hosmane, Abhisek Dubey, Abhisek Agarwal, Ram Kishun Verma, A study to estimate prevalence and risk factors of Obstructive Sleep Apnoea Syndrome in a semi-urban Indian population , Monaldi Archives for Chest Disease: Vol. 87 No. 1 (2017)
- Josuel Ora, Angelo Coppola, Andrea Perduno, Gian Marco Manzetti, Ermanno Puxeddu, Paola Rogliani, Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients , Monaldi Archives for Chest Disease: Vol. 92 No. 2 (2022)
- S. Dragonieri, O. Tongoussouva, A. Zanini, A. Imperatori, A. Spanevello, Markers of airway inflammation in pulmonary diseases assessed by induced sputum , Monaldi Archives for Chest Disease: Vol. 71 No. 3 (2009): Pulmonary series
- N. Barbarito, A. Vaghi, E. De Mattia, Prevalence of airflow obstruction according GOLD, ATS and ERS criteria in symptomatic ever-smokers referring to a Pulmonary Rehabilitation Department , Monaldi Archives for Chest Disease: Vol. 75 No. 3 (2011): Pulmonary series
- Alfredo Monteverde, Valeria Carlino, Giulia Ganci, Giuseppe Taormina, Mario Barbagallo, Treatment of heart failure with preserved ejection fraction , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Domenico Galzerano, Claudio Pragliola, Mohamed Al Admawi, Mario Mallardo, Sara Di Michele, Carlo Gaudio, The role of 3D echocardiographic imaging in the differential diagnosis of an atypical left atrial myxoma , Monaldi Archives for Chest Disease: Vol. 88 No. 3 (2018)
- Naoto Ishimaru, Hisashi Ohnishi, Mao Fujii, Masako Yumura, Sho Yoshimura, Saori Kinami, Microscopic polyangiitis presented with biopsy-confirmed pleuritis , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
<< < 11 12 13 14 15 16 17 18 19 20 > >>
You may also start an advanced similarity search for this article.
